Welcome to Pharmaprojects’ 2017 review of trends in pharmaceutical R&D. Our analysts have compiled a compelling view of R&D, past, present, and future. This infographic provides an overview of this analysis. Download the full report for free here https://goo.gl/1tASPp for a detailed look at the Pharma R&D market.

1. Pharma R&D Annual Review 2017
CLICK HERE FOR MORE INFO
REQUEST A DEMO
FIND OUT MORE HERE
Pharma, like the movies, is getting
bigger and bolder, growing by pretty
much every measure in 2016. Here is
our quick guide to the most important
plots, twists and actors in today’s
biopharmaceutical marketplace.
Pharma R&D Annual Review 2016
WHAT A PERFORMANCE!
14,872 8.4%
pipeline projects in 2017
increase on corresponding
figure from 2016
increase through 2015–16
and 8.8% the previous year11.5%
The 2016 Global Pipeline
Preclin Phase I Phase II Phase III Pre-reg Registered Launched Suspended
6861
7493
1856
2064
2261
2357
954
197
220
102
116
1273
1395
70
79
1025
The 2017 pipeline by phase
Baby boom leads the way, but growth throughout the family
Preclinical
INCREASE INCREASE INCREASE
Phase III
INCREASE
in projects
(up by 632 drugs)
in projects
(up by 208 drugs)
in projects
(up by 96 drugs)
in projects
(up by 71 drugs)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
15000
8000
0
2016 2017
Distribution of R&D Companies
Where Is The Action Taking Place?
2
3
4
5
6
7
8
9
10
GlaxoSmithKline 250 (242)
Pfizer 232 (217)
Merck & Co. 229 (223)
Johnson & Johnson 214 (227)
AstraZeneca 213 (231)
Roche 206 (211)
Sanofi 193 (199)
Bristol-Myers Squibb 144 (136)
Takeda 141 (137)
Novartis sits at the top of the tree.
The Swiss conglomerate’s
ascendancy to pole position is
compounded by the fact that it
originated a greater proportion
of its pipeline itself compared to GSK.
No. of Drugs in Pipeline 2017 (2016): 251(240)
47% 3% Germany
3% France
6% UK
19%
Asian firms now account
for 19% of companies,
up from 16% last year,
and driven not only by
further expansion in China,
but also by general growth
throughout the region.
Asia companies up from
16% a year ago
USADown 1%
from 2016
R&D Activity
1
11.1%
Anticancer
Biotechnology
Neurological
Anti-Infective
Reformulations
Alimentary/Metabolic
Musculoskeletal
Cardiovascular
Immunological
Dermatological
Sensory
Blood & Clotting
Genitourinary
Hormonal
Antiparasitic
4176
2513
2542
2221
2468
2080
2132
1999
2149
1499
1574
950
962
869
917
831
911
855
845
725
797
608
597
630
254
275
121
128
652
4845
4051
4481
2016 2017
16.0%INCREASE
Drugs in the pipeline
with a cancer focus
32.6%
Drugs in development that
have an oncological target
Anti-infectives
GROWTH
Anticancer, other
2231 Projects
Anticancer, immunological
2001 Projects
TOP TWO THERAPIES BASED ON PHARMAPROJECTS CATEGORIES
As biologicals proliferate, is the small
molecule becoming a dinosaur?
In synthetic chemicals
(Small molecules)
1
2
3
4
5
6
7
8
9
Chemical, synthetics
Origin
Biological, protein, antibody
Biological, protein, recombinant
Biological, protein
Chemical, synthetic, peptide
Biological, virus particles
Biological, cellular
Biological, nucleic acid, viral vector
Chemical, synthetic, nucleic acid
10 Biological, cellular, autologous
7,855 (7,540)
No of Active drugs 2017 (2016)
1,687 (1,466)
861 (892)
545 (439)
468 (434)
367 (303)
352 (210)
329 (297)
323 (301)
251 (214)
4.2%
INCREASE
Monoclonal antibody-
based drugs
15.1%
INCREASE
The industry is involved in transferring
a significant proportion of its eggs
into the biotech basket.
BIOTECH-DERIVED DRUGS
NOW APPEAR IN OVER A
THIRD OF R&D ACTIVITY
RISE IN NUMBERS OF DRUGS RECEIVING ORPHAN DRUG STATUS
OR AN EXPEDITED REVIEW DESIGNATION 2014–2016
2014 2015 2016
There were slightly fewer orphan
drug statuses granted than
during the previous year.
Orphan Drug Status Granted Expedited Review Status Granted
326 394 182 369 188
As the curtain falls on another year of pharma
IN THE LIMELIGHT
Top 25 Therapies
157
1 2
Top10Pharma
Companies
BY SIZE OF
PIPELINE
Top 10 Origins of
Pipeline Drugs
BY NUMBER OF
ACTIVE DRUGS
Big beasts still dominate,
but Novartis is the new
king of the jungle
USA
Rest of Europe
Rest of Asia Pacific
China
UK
Canada
Japan
Germany
France
C & S America/Africa
Respiratory
47%
11%
5%
3%
16%
6%
5%
3%
3% 1%
48%
9%
4%
3%
2%
18%
5%
5%
3%
3%
2016 2017
16%The Rest of Europe
Darwinian forces mean pharma’s
creatures must find their niches
So it would seem that, for yet another year,
the take-home message on pharma R&D
can be summed up most simply as:
there’s more of it than ever.
Survival of the fittest
Phase II
Top Companies
The pharma forest is teeming with life
Total R&D pipeline size
16,000
14,000
12,000
10,000
8,000
6,000
4,000
2,000
0
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Source:Pharmaprojects®,January2017
Pharma R&D
By Numbers
Welcome to Pharmaprojects’ 2017
review of trends in pharmaceutical R&D
9.2% 11.2% 7.4%4.2%
Types of pipeline drugs
Phase I